Myth 1: "Prostate Cancer Only Affects Old Men"

---

This is one of the most dangerous myths because it prevents screening in exactly the age group where early detection would make the most difference. Prostate cancer does become more common with age — the median age at diagnosis globally is 66.

But "more common in older men" is not the same as "only in older men."

Men in their 40s and early 50s are diagnosed with prostate cancer regularly. A man in his late 40s diagnosed with Gleason 8 prostate cancer that went undetected because he assumed he was too young to worry is not a rare scenario.

Uro-oncologists at major Indian hospitals see this pattern with uncomfortable frequency among patients from Nigeria, Kenya, and Bangladesh.

Men with a first-degree relative — father or brother — who had prostate cancer are at approximately double the population risk and should begin PSA screening discussions at 40, not 50.

Men of African descent have higher incidence and earlier average age at diagnosis than men of Asian or European descent — a fact critically underappreciated in communities where this myth is most prevalent.

Myth 2: "If I Had Prostate Cancer I Would Know — I Would Feel Something"

---

This is the myth responsible for the single greatest delay in prostate cancer diagnosis. Early prostate cancer — the stage at which it is most curable — produces no symptoms whatsoever.

None. No pain, no urinary difficulties, no blood in the urine, no fatigue, no unexplained weight loss.

Urinary symptoms — difficulty starting urination, weak stream, frequent urination at night — are extremely common in middle-aged and older men. But they are caused by benign prostatic hyperplasia (BPH), not by cancer.

The prostate enlarges naturally with age, and that enlargement causes urinary symptoms regardless of whether cancer is present.

A man who develops urinary symptoms assumes something is wrong and gets checked — and finds BPH, not cancer.

A man with prostate cancer but no symptoms assumes everything is fine and does not get checked — and finds cancer at stage 3 or 4 when symptoms finally appear because the cancer has grown large enough, or has spread to bone.

Myth 3: "Prostate Surgery Always Causes Permanent Impotence"

---

The fear of post-surgical impotence is probably the most common reason men in South Asian and African communities refuse or delay prostate cancer surgery. It is a fear rooted in reality — older open prostatectomy techniques did frequently cause permanent erectile dysfunction.

But those techniques are not what is done at high-volume centres in 2025.

Nerve-sparing robotic radical prostatectomy — the technique used at Fortis FMRI, Medanta, Apollo Delhi, and Kokilaben — preserves the neurovascular bundles running alongside the prostate that are responsible for erectile function.

When both bundles are preserved in a bilateral nerve-sparing procedure, 50 to 70 percent of men under 65 with good pre-operative function recover erections sufficient for sexual activity within 12 to 24 months.

The recovery is not immediate — this needs to be stated clearly. Erectile function after robotic prostatectomy is not present in the first weeks or months post-surgery. It returns gradually over 12 to 24 months as the nerves recover.

Men who begin penile rehabilitation early — using PDE-5 inhibitors like sildenafil shortly after surgery — have significantly better long-term outcomes than those who wait.

The surgeon's volume and technique matter enormously here. A surgeon performing 200 nerve-sparing procedures per year achieves meaningfully better potency preservation rates than one performing 20.

This is why choosing the right specialist — not just the right hospital — is the single most important decision in a prostatectomy.

Myth 4: "A High PSA Definitely Means I Have Cancer"

---

A raised PSA creates enormous anxiety. That anxiety is partly proportionate — a significantly elevated PSA does increase the probability of prostate cancer being present.

But probability is not certainty, and a PSA result alone does not diagnose cancer or tell you anything about stage.

PSA stands for prostate-specific antigen — not prostate cancer antigen. It is produced by all prostate cells, healthy and cancerous alike.

Benign prostatic hyperplasia, prostatitis, a urinary tract infection, vigorous exercise, and ejaculation within 48 hours of the test all raise PSA.

A PSA of 7.4 in a man with a large benign prostate and a mild urinary infection might have nothing to do with cancer at all.

In the grey zone of 4 to 10 ng/mL — where many men find themselves — the probability of cancer being present when biopsied is approximately 25 percent. That means three out of four men in this range will biopsy negative.

Even at PSA above 10, more than half of men do not have cancer.

The PSA is a signal to investigate further. It is not a diagnosis. A multiparametric MRI, a PSA density calculation, and — if indicated — a targeted biopsy are the tools that turn a raised PSA into an actual answer.

Panicking about a PSA result before those investigations are complete is both premature and medically unnecessary.

Myth 5: "Prostate Cancer Is a Death Sentence"

---

This myth is particularly destructive because it prevents men from seeking diagnosis — and therefore from receiving treatment at a stage where cure is genuinely achievable.

The experience of one family member who died from prostate cancer — almost certainly diagnosed late, in a system with limited treatment resources — is not representative of what prostate cancer means in 2025 at a modern cancer centre.

The prostate cancer-specific survival for localised disease — cancer confined within the prostate — is above 97 percent at ten years regardless of whether treated with surgery or radiation.

For locally advanced disease that has breached the prostate capsule but not spread to distant organs, ten-year cancer-specific survival is above 85 percent with appropriate multimodal treatment.

Even metastatic prostate cancer — cancer that has spread to lymph nodes or bones — is not automatically fatal within a year.

Men with metastatic hormone-sensitive disease who receive combination ADT plus docetaxel plus abiraterone have median survival times measured in years, not months.

Men with metastatic disease live active, functional lives for years on modern treatment.

The trajectory of prostate cancer treatment has changed dramatically in the last ten years. Lu-177 PSMA therapy, PARP inhibitors, and second-generation hormonal agents have transformed the metastatic disease landscape.

The uncle who died "within a year" most likely did not have access to these treatment options.

Myth 6: "Gleason 6 Means I Need Surgery Straight Away"

---

This is not a myth about cancer biology that patients invented. It is a myth that is frequently reinforced by surgeons — particularly those in private practice where the financial incentive favours intervention over monitoring.

No reputable international oncology guideline recommends immediate surgery as the automatic response to Gleason 6 (Grade Group 1) prostate cancer.

Gleason 6 prostate cancer is real cancer. It contains abnormal cells. But it grows so slowly that the vast majority of men with this diagnosis die of something entirely unrelated to their prostate before this cancer ever becomes life-threatening.

The ten-year prostate cancer-specific mortality for Grade Group 1 disease is below three percent.

Active surveillance — close monitoring with regular PSA tests, MRI, and occasional repeat biopsies — is endorsed as the preferred management strategy for Gleason 6 disease in virtually every major guideline, including the EAU and AUA.

It is not a delay. It is the clinically correct approach.

A man who has immediate surgery for Gleason 6 cancer may expose himself to the side effects of prostatectomy — potential urinary incontinence, erectile dysfunction, recovery time — for a cancer that would likely never have harmed him during his lifetime.

If a surgeon is recommending immediate surgery for Gleason 6 without any discussion of active surveillance, a second opinion is not optional. It is essential.

Myth 7: "Cancer Treatment in India Cannot Match Western Standards"

---

This myth is understandable but factually incorrect for India's leading cancer hospitals.

It conflates the enormous variation within Indian healthcare — which is real — with the specific reality of JCI-accredited tertiary cancer centres, which operate to a completely different standard.

The Da Vinci Xi robotic surgical system used at Fortis FMRI Gurgaon is identical — same generation, same software, same instrument set — to the one used at Johns Hopkins Hospital in Baltimore.

The Varian TrueBeam linear accelerator used at Medanta is the same machine used at the Christie Hospital in Manchester.

The PSMA PET-CT scanning available at Apollo Delhi meets the same technical specifications as equivalent scanners in Germany or Australia.

The uro-oncologists at India's major cancer centres have trained at institutions in the USA, UK, and Europe. They publish in the same international journals. They attend the same conferences. They follow the same EAU, NCCN, and ESMO guidelines.

The gap in technology and specialist expertise between India's top five cancer hospitals and a comparable Western academic centre has largely closed over the last decade.

What remains different is the cost. Robotic prostatectomy that costs USD 25,000 to 55,000 in the USA costs USD 6,500 to 9,000 in India.

That cost difference does not reflect a quality difference. It reflects a structural difference in how healthcare is priced and delivered.

Myth 8: "Herbal Remedies and Traditional Medicine Can Cure Prostate Cancer"

---

This myth costs lives. Not because herbal remedies are universally dangerous — some have real pharmacological activity and potential benefit in oncology research.

Using them as a replacement for proven treatment, while a curable cancer becomes incurable, is a tragedy that plays out with painful regularity.

No plant compound, no traditional preparation, no dietary supplement has been shown in a rigorous randomised controlled trial to cure prostate cancer, to reverse a Gleason 8 tumour, or to produce an undetectable PSA in a man with established disease.

The laboratory data on compounds like curcumin, saw palmetto, and various African herbal preparations is sometimes interesting but a very long way from clinical proof.

The specific danger in this myth is timing. A man with Gleason 7 localised prostate cancer who delays surgery or radiation for six months while trying a herbal regimen may still be curable at six months.

One year or two years of delay, by which time the cancer may have progressed beyond the capsule, is a different matter entirely. The window of cure is not infinite.

Integrative medicine approaches — yoga, dietary modification, mindfulness, certain supplements under oncologist supervision — can genuinely support quality of life alongside conventional treatment.

They are complementary to evidence-based cancer treatment, not a replacement for it.

Frequently Asked Questions

---